plausibl
dock
librari
million
molecul
target
sever
day
week
molecul
screen
commerci
avail
may
rapidli
test
find
new
lead
although
dock
retain
import
liabil
calcul
affin
accur
even
reliabl
rank
order
highscor
molecul
often
distinguish
like
unlik
ligand
often
hit
rate
summar
improv
librari
target
qualiti
method
support
advanc
open
access
resourc
make
dock
access
recent
dock
screen
new
ligand
sketch
bind
crystallograph
vivo
assay
support
like
techniqu
control
crucial
key
experiment
one
review
control
dock
campaign
find
ligand
new
chemotyp
often
reveal
new
biolog
may
dock
greatest
impact
next
year
correspond
author
jji
phone
begin
simul
protein
structur
promot
structurebas
ration
drug
design
techniqu
struggl
meet
initi
promis
earli
discoveri
continu
domin
empir
method
still
past
decad
drug
structur
comput
genuin
pivot
begun
appear
close
drug
clear
link
structurebas
discoveri
design
clinic
use
may
exceed
deriv
anoth
wide
herald
approach
highthroughput
screen
ht
central
techniqu
structurebas
discoveri
molecular
dock
dock
screen
librari
molecul
interrog
complement
protein
structur
figur
molecul
librari
hundr
thousand
orient
may
sampl
protein
site
everi
orient
hundr
conform
increasingli
altern
protein
conform
also
consid
overal
ligand
complex
may
calcul
larg
librari
screen
rank
use
score
function
consid
sever
polar
nonpolar
solventdepend
score
term
approxim
sever
firstprincipl
reason
dock
screen
might
never
work
among
dock
emphasi
throughput
ensur
undersampl
state
princip
protein
conform
order
water
network
even
ligand
conform
heavili
sampl
energi
weight
among
poorli
treat
ignor
dock
complex
rare
fulli
relax
lead
amount
irrevers
work
ligand
protein
desolv
energi
best
approxim
often
entangl
dock
interact
energi
score
score
ignor
import
term
among
other
interact
polariz
even
term
includ
rare
wellparametr
divers
molecul
dock
screen
deck
dock
score
energi
calcul
allatonc
rather
via
small
perturb
central
techniqu
free
energi
perturb
alchem
thermodynam
integr
least
pretend
calcul
rel
absolut
affin
bind
calcul
sampl
candid
ligand
configur
one
term
could
ensur
failur
dock
screen
plausibl
ligand
success
reconcil
weak
approach
like
largescal
screen
dock
seek
new
observ
case
new
ligand
unanticip
previou
seri
hope
confer
new
biolog
emphas
throughput
poll
mani
possibl
toler
fals
posit
fals
neg
long
enough
experiment
confirm
posit
found
wherea
dock
fail
reason
sketch
happen
crude
dock
score
success
reduc
mani
million
molecul
screen
rel
small
number
plausibl
candid
candid
avail
commerci
industri
user
inhous
librari
cost
failur
cheap
even
success
rate
often
suffici
justifi
enterpris
describ
practic
strategi
success
dock
campaign
resourc
allow
prosecut
wide
commun
specialist
enterpris
depend
close
integr
dock
screen
experiment
test
candid
consid
strategi
pick
hit
test
critic
evalu
experiment
test
summar
recent
method
develop
dock
well
review
elsewher
close
discuss
major
contribut
dock
earli
discoveri
medicin
chemistri
chemic
biolog
illumin
genuin
new
chemotyp
target
activ
biolog
interest
prospect
screen
larg
librari
molecul
dock
complement
bind
site
focu
commerci
avail
molecul
tabl
academ
laboratori
inhous
librari
pharmaceut
research
organ
ensur
molecul
may
readili
acquir
test
crucial
success
enterpris
anticip
failur
rate
zinc
incorpor
mani
amount
million
commerci
avail
druglik
compound
repres
precalcul
readytodock
format
zinc
easili
subdivid
physic
properti
correspond
current
opinion
field
fragmentlik
leadlik
subset
especi
program
optim
parallel
execut
dock
allow
limit
seat
licens
full
screen
may
complet
week
two
wall
time
typic
academ
cluster
emerg
end
calcul
list
molecul
rankord
complementar
bind
site
dock
score
function
one
highscor
configur
bind
site
may
visual
individu
priorit
purchas
test
dock
ignor
approxim
key
energi
term
screen
compound
simpli
misrepres
molecul
strain
conform
ligand
may
dock
pk
valu
may
miscalcul
highenergi
tautom
sampl
among
potenti
problem
even
error
affect
small
percentag
dock
librari
scum
often
rise
top
instanc
highenergi
ligand
conform
mischarg
molecul
make
interact
lowenergi
state
result
artifici
favor
score
like
highthroughput
method
rapid
filter
artifact
crucial
chemoinformat
control
similar
known
chemotyp
sinc
purpos
dock
screen
often
discoveri
new
chemic
matter
complement
bind
site
dissimilar
molecul
could
found
qsar
instanc
sensibl
elimin
dock
hit
would
found
topolog
similar
alon
control
insist
journal
includ
one
addit
autom
typic
postdock
filter
visual
evalu
dock
highrank
candid
bring
integr
knowledg
system
physic
chemistri
evalu
ht
campaign
hitpick
parti
involv
two
eight
scientist
broader
team
help
select
final
set
highrank
molecul
acquir
physic
test
molecul
though
alway
top
score
molecul
screen
rare
top
rank
raw
dock
score
rather
molecul
may
select
divers
favor
interact
instanc
priorit
key
hydrogen
bond
import
priorit
favor
interact
bia
ligand
toward
known
chemotyp
depriorit
ligand
unfavor
featur
dock
score
function
properli
penal
mention
common
exampl
includ
ligand
conform
strain
improp
tautomer
improp
proton
ioniz
group
challeng
problem
molecular
represent
requir
rel
high
level
calcul
given
molecul
littl
surpris
million
molecul
error
made
sometim
error
slip
autom
librari
creation
pipelin
caught
experienc
medicin
chemist
biophysicist
depriorit
thu
often
case
molecul
rank
priorit
molecul
rank
better
hitpick
parti
secondari
benefit
train
wider
team
molecular
interact
medicin
chemistri
target
biolog
dock
current
accuraci
often
find
acquir
test
new
molecul
suffici
find
two
five
new
ligand
famili
sourc
mani
compound
commerci
vendor
typic
econom
feasibl
even
academ
laboratori
mani
may
consid
pharmaceut
research
organ
number
compound
often
suit
low
throughput
care
assay
dock
hit
test
target
better
bind
site
like
aminerg
g
protein
coupl
receptor
gpcr
number
compound
acquir
might
lower
target
solvent
access
site
like
proteas
number
compound
acquir
higher
success
rate
lower
improv
dock
method
compound
access
eas
test
chang
number
logic
test
enough
molecul
ensur
suffici
number
plausibl
new
lead
chemotyp
given
expect
hit
rate
remain
valid
wherea
remain
dock
campaign
molecul
test
whatsoev
interest
lead
experi
delight
sometim
surpris
docker
often
reveal
hit
molecul
activ
bind
function
assay
screen
techniqu
initi
experiment
hit
must
initi
view
suspicion
pockmark
artifact
origin
experiment
artifact
extens
review
broadli
divid
molecul
pan
assay
interfer
pain
chemotyp
promiscu
hitter
coval
act
molecul
see
molecul
interfer
assay
spectroscopi
molecul
form
colloid
aggreg
figur
hit
pain
chemotyp
alway
patholog
fdaapprov
worldwid
drug
contain
pain
chemotyp
often
flag
detail
followup
simpli
discard
mani
pain
chemotyp
rapidli
identifi
use
publicli
avail
filter
eg
http
appendix
share
singl
mechan
fall
singl
set
control
interrog
classic
doserespons
curv
lack
incub
effect
impervi
mild
reduct
specif
versu
counterscreen
enzym
favor
featur
argu
artifactu
activ
coval
spectroscop
interfer
molecul
specif
physic
mechan
control
appendix
far
common
artifact
virtual
highthroughput
screen
campaign
colloid
aggreg
molecul
screen
librari
aggreg
relev
concentr
colloid
form
sequest
artifactu
inhibit
occasion
activ
protein
fortun
mechan
readili
control
appendix
studi
omit
control
experiment
artifact
may
wast
person
year
effort
hopeless
compound
progress
detail
biophys
test
new
inhibitor
mechan
alway
illumin
irrespect
whether
one
suspect
artifact
understand
tendenc
fall
love
earli
hit
hard
experi
suggest
obscur
wellbehav
optimiz
molecul
one
would
find
distract
fals
posit
measur
publish
full
concentrationrespons
curv
simpl
crucial
step
toward
much
learn
steep
curv
well
sampl
recommend
sampl
everi
halflog
concentr
low
high
enough
concentr
establish
upper
lower
baselin
step
measur
full
bind
constant
enzymolog
k
radioligand
displac
reporterfre
method
isotherm
titrat
calorimetri
surfac
plasmon
reson
relat
techniqu
full
curv
measur
report
investig
long
sought
fundament
breakthrough
would
address
dock
core
liabil
perhap
entangl
approxim
dock
resist
dramat
improv
content
increment
progress
still
time
made
notic
improv
method
ad
new
polar
interact
term
flexibl
water
metal
coordin
protein
prepar
tool
parallel
combinatori
librari
dock
new
sampl
method
treatment
order
water
often
use
version
inhomogen
solvat
theori
import
improv
dock
improv
qualiti
extent
chemic
librari
among
wide
use
zinc
databas
grown
commerci
avail
molecul
decad
ago
million
threedimension
parametr
dockabl
structur
avail
qualiti
molecul
repres
also
improv
draw
improv
treatment
molecular
proton
tautomer
well
conform
librari
like
sampl
experiment
observ
form
final
druggabl
dock
target
improv
drug
act
membran
protein
year
ago
structur
pharmacolog
relev
membran
protein
determin
someth
chang
dramat
past
decad
receptor
wellform
ligand
bind
site
often
wellsuit
complementaritybas
approach
like
dock
afford
hit
rate
almost
logord
better
experienc
open
site
typic
solubl
protein
hit
logord
better
affin
unglamor
seem
increment
improv
dock
method
librari
target
select
continu
central
progress
field
next
year
would
big
breakthrough
dock
look
like
one
could
accur
calcul
bind
free
energi
even
accur
rankord
among
top
dockingpriorit
hitlist
molecul
impact
would
enorm
would
justifi
substanti
invest
principl
biophys
base
calcul
accur
bind
constant
hand
via
alchem
method
thermodynam
integr
though
method
begin
test
prospect
even
recent
advanc
long
molecular
dynam
simul
howev
approach
remain
far
slow
practic
scale
larg
librari
screen
calcul
k
valu
million
molecul
divers
librari
would
take
decad
even
increas
comput
power
like
next
sever
year
meanwhil
lack
proper
parametr
librari
molecul
ensur
larg
error
even
highend
method
accur
biophys
method
may
impact
larg
scale
screen
next
year
rescor
top
tranch
dock
hitlist
help
priorit
final
get
test
also
improv
accuraci
dock
geometri
crucial
enterpris
dock
add
campaign
progress
initi
discoveri
optim
goal
highend
biophys
method
may
seem
modest
success
would
great
impact
fragmentbas
discoveri
address
chemic
space
problem
screen
molecul
typic
smaller
nonhydrogen
atom
amu
chemotyp
possibl
combinatori
explod
molecul
grow
size
collaps
shrink
fragment
screen
span
far
greater
percentag
chemotyp
screen
druglik
amu
even
leadlik
amu
molecul
power
fragment
screen
chemotyp
discoveri
empir
fragment
librari
rare
molecul
owe
low
throughput
biophys
method
use
assay
less
need
cover
even
known
biorelev
chemotyp
empir
librari
dwarf
million
fragment
simpli
commerci
avail
screen
commerci
avail
fragment
beyond
biophys
screen
method
use
fragmentbas
discoveri
would
take
day
decent
academ
cluster
dock
concern
fragment
dock
method
optim
larger
molecul
dock
would
lead
promiscu
predict
fragment
pose
worri
merit
newli
discov
dock
fragment
often
less
fidel
xray
structur
larger
molecul
mani
field
believ
fragment
dock
remain
riski
still
mani
predict
fragment
geometri
fairli
accur
hitrat
fragment
dock
logord
better
leadlik
druglik
screen
potenti
liabil
fragment
dock
fill
chemotyp
hole
empir
librari
sometim
lead
hit
much
higher
affin
ligand
effici
empir
screen
alon
gap
librari
coval
probe
compel
still
bitter
experi
fals
posit
empir
screen
librari
scrub
clean
hot
electrophil
make
hard
intent
screen
larg
librari
coval
ligand
convers
electrophil
remain
common
among
commerci
librari
among
leadlik
molecul
zinc
act
coval
michael
acceptor
epoxid
boron
acid
nitril
warhead
http
covalentdockingorg
recent
sever
method
introduc
intent
screen
librari
coval
ligand
typic
modifi
exist
noncoval
score
function
sampl
close
bond
approach
discount
van
der
waal
clash
impli
format
coval
adduct
favor
circumst
method
predict
pose
high
fidel
subsequ
crystal
structur
prospect
hit
rate
substanti
higher
experienc
noncoval
dock
retain
decent
specif
offtarget
area
new
tool
rapidli
introduc
widespread
interest
error
dock
target
homolog
model
might
seem
riski
hand
number
target
experiment
structur
outstrip
sever
logord
plausibl
compar
model
may
calcul
model
templat
suffici
sequenc
ident
possibl
fortifi
constraint
techniqu
provid
use
structur
ligand
discoveri
inde
prospect
headtohead
studi
dock
compar
model
subsequ
crystal
structur
receptor
hit
rate
hit
affin
return
structur
multipl
dock
screen
homolog
model
report
ligand
substrat
deorphan
studi
inde
one
approv
drug
structurebas
design
play
pivot
role
aliskiren
homolog
model
lead
complex
long
predat
crystal
structur
even
error
dock
protein
structur
model
target
compar
model
greatli
expand
dockabl
target
structurebas
screen
reliabl
return
novel
chemotyp
unrel
previous
known
ligand
target
multipl
way
protein
structur
recogn
given
ligand
chemotyp
particular
bind
site
recogn
multipl
unrel
scaffold
even
wellpreced
target
structurebas
screen
find
new
ligand
without
anteced
previou
medicin
chemistri
though
strong
logic
new
ligand
chemistri
lead
new
biolog
often
abil
break
medicin
chemistri
box
discov
new
chemotyp
dock
screen
may
find
import
contribut
next
year
may
illustr
exampl
class
c
bacteri
enzym
major
sourc
resist
antibiot
like
penicillin
cephalosporin
clinic
wherea
inhibitor
clavulan
wellknown
grave
liabil
class
c
enzym
ic
valu
modest
wors
still
upregul
express
enzym
meant
inhibit
actual
increas
resist
dock
screen
new
inhibitor
class
c
ampc
discov
famili
thiophenecarboxyl
sulfonamid
inhibitor
dissimilar
known
includ
clavulan
found
crystallographi
bind
site
inhibit
enzym
potenc
unlik
clavulan
new
inhibitor
simpli
inhibit
enzym
bacteri
cell
cultur
upregul
express
thu
unlik
classic
inhibitor
synergist
antagonist
primari
antibiot
ceftazidim
piperacillin
figur
orphan
enzym
thermatoga
maritim
whose
structur
determin
part
structur
genom
initi
wherea
sequenc
structur
could
readili
assign
amidohyrolas
superfamili
function
unknown
autom
assign
misannot
cytosin
deaminas
dock
screen
metabolit
repres
highenergi
intermedi
enzym
structur
reveal
sever
analog
adenosin
toprank
hit
suggest
went
deamin
reaction
purin
ring
reveal
highenergi
intermedi
form
dock
among
sadenosyl
homocystein
test
found
excel
substrat
second
order
rate
constant
mol
subsequ
crystallographi
confirm
product
predict
deamin
sinosyl
homocystein
superpos
well
dock
pose
figur
convers
sadenosin
homocystein
inosyl
deriv
suggest
previous
unknown
sadenosyl
homocystein
degrad
pathway
bacteria
similar
strategi
recent
illumin
function
orphan
also
known
learn
memori
gpcr
screen
gener
function
assay
small
drug
librari
benzodiazepin
lorazepam
found
posit
alloster
modul
pam
bind
therapeut
target
gaba
ion
channel
lorazepam
use
biolog
probe
function
accordingli
thousand
model
construct
use
model
priorit
abil
highli
rank
lorazepam
versu
known
decoy
molecul
initi
empir
screen
subsequ
seri
dock
screen
test
optim
led
pam
improv
efficaci
lorazepam
unlik
lorazepam
new
molecul
measur
activ
gaba
channel
specif
versu
sequencerel
orphan
receptor
molecul
dub
ogerin
ligand
advanc
vivo
function
studi
screen
mous
behavior
assay
ogerin
reduc
fearcondit
contextbas
learn
assay
consist
high
express
hippocampu
associ
modal
convers
ogerin
effect
cuebas
learn
associ
amygdala
effect
even
contextbas
learn
knockout
mice
close
analog
ogerin
littl
effect
vitro
also
littl
effect
vivo
observ
support
ontarget
effect
ogerin
vivo
extens
function
formal
dark
receptor
learn
memori
recent
studi
suggest
gpcr
play
role
develop
irrit
bowel
syndrom
may
target
new
therapeut
current
select
antagonist
receptor
report
due
high
degre
homolog
close
relat
protein
famili
member
huang
cowork
recent
use
crystal
structur
agonist
bound
discov
novel
select
antagonist
chemotyp
receptor
creat
inducedfit
model
use
antagonist
dock
inhous
collect
divers
compound
sever
new
compound
emerg
includ
chemotyp
contain
proton
triazin
ring
instead
convent
tertiari
aliphat
amin
novel
chemotyp
led
subtyp
select
compound
receptor
test
vivo
select
antagonist
substanti
attenu
viscer
hypersensit
irrit
bowel
syndrom
rat
model
scaffold
repres
new
avenu
develop
select
antagonist
treatment
relat
diseas
ra
relat
solubl
gtpbase
kinas
perhap
protein
implic
cancer
long
resist
modul
high
affin
gdp
gtp
theodorescu
meroueh
use
molecular
dock
screen
discov
inhibitor
modul
gdpform
raslik
kinas
rala
ralb
inhibitor
activ
vitro
also
ralmedi
cell
spread
murin
fibroblast
anchorageindepend
growth
human
cancer
cell
line
two
compound
select
ral
versu
ra
rho
kinas
inhibit
tumor
growth
xenograph
mous
model
level
similar
deplet
ral
sirna
result
illustr
abil
structurebas
approach
discov
chemotyp
long
elud
pure
empir
approach
past
decad
dock
advanc
increment
improv
least
size
qualiti
dock
librari
true
breakthrough
rapid
calcul
bind
affin
rank
divers
compound
even
occur
postdock
list
priorit
molecul
would
chang
field
even
without
breakthrough
steadi
optim
brought
field
often
find
new
lead
matter
biolog
relev
target
great
opportun
dock
applic
discoveri
genuin
new
molecul
preced
unpreced
target
wherea
strong
reason
new
chemotyp
lead
new
biolog
often
even
wellstudi
target
opportun
use
dock
screen
new
chemotyp
discoveri
increasingli
avail
specialist
commun
via
open
access
tool
tabl
size
chemic
librari
routin
use
structurebas
screen
moreov
grown
steadili
sinc
first
introduc
year
ago
earli
earli
approach
million
anoth
logord
expans
sight
far
exceed
empir
librari
except
perhap
dnaencod
day
conserv
leadlik
dock
campaign
might
screen
six
million
molecul
avail
vendor
within
coupl
week
one
will
wait
coupl
month
number
would
grow
million
leadlik
molecul
natur
larg
librari
interest
structurebas
method
priorit
tini
percentag
plausibl
ligand
among
vast
number
decoy
alway
concern
ad
librari
molecul
simpli
drown
signal
nois
still
result
past
sever
year
multipl
target
multipl
laboratori
suggest
dock
problem
distinguish
plausibl
implaus
molecul
least
wellform
bind
site
also
suggest
larger
librari
led
novel
often
potent
chemotyp
though
admittedli
investig
control
way
next
sever
year
dock
greatest
impact
may
pragmat
applic
biomed
problem
new
chemic
matter
confer
new
biolog
noncoval
dock
hit
act
coval
artifact
often
via
reactiv
center
present
dock
molecul
impur
rapid
counterscreen
irrevers
inhibit
incub
target
protein
hit
appar
ic
dilut
ic
ratio
may
cours
chosen
inhibit
rapidli
revers
inhibit
dilut
drop
full
inhibit
ratio
dilut
chang
inhibit
littl
support
coval
activ
legitim
slow
offrat
inhibit
anoth
altern
molecul
rare
among
initi
screen
hit
experi
work
solubl
protein
relat
experi
measur
offrat
may
adapt
membran
protein
chemotyp
repres
molecul
often
occur
among
promiscu
molecul
fail
progress
sever
tool
avail
rapidli
detect
chemotyp
includ
http
hit
pain
function
invalid
make
care
test
mechan
import
recommend
counterscreen
molecul
unrel
target
determin
whether
compet
ligand
known
site
whether
concentrationrespons
curv
wellbehav
figur
red
curv
compound
absorb
light
fluoresc
region
use
measur
activ
look
like
hit
via
assay
interfer
molecul
inhibit
report
enzym
like
luciferas
spectroscop
interfer
chang
linearli
concentr
follow
beer
law
rather
loglinearli
singl
site
isotherm
inhibitor
report
may
counterscreen
sometim
compound
pretend
contain
reactiv
impur
activ
molecul
test
puriti
anyth
purifi
ac
journal
often
request
puriti
better
perhap
largest
singl
sourc
artifact
earli
discoveri
colloid
aggreg
small
molecul
particl
nm
radiu
adsorb
protein
without
specif
partial
denatur
molecul
typic
screen
deck
aggreg
relev
concentr
ensur
hit
reflect
colloidform
domin
screen
virtual
empir
control
fortun
mechan
inhibit
may
readili
control
inhibit
attenu
small
amount
nonion
deterg
compound
like
aggreg
typic
use
vv
freshli
prepar
tritonx
vv
membran
cell
assay
ii
direct
observ
particl
nm
size
rang
dynam
light
scatter
dl
format
particl
guarante
promiscu
inhibit
worri
sign
iii
cellbas
assay
colloid
particl
precipit
centrifug
assay
run
assay
media
compound
much
effect
spin
suggest
colloid
aggreg
iv
noncompetit
inhibit
high
hill
slope
classic
reason
noncompetit
inhibit
cooper
bind
latter
rare
earli
discoveri
two
togeth
suggest
aggreg
v
attenu
inhibit
increas
target
concentr
except
receptor
concentr
k
ratio
high
increas
receptor
concentr
affect
inhibit
wellbehav
inhibitor
much
reduc
colloid
aggreg
increas
steep
respons
curv
figur
experi
access
solubl
protein
john
j
irwin
train
organ
chemistri
crystallographi
jack
dunitz
eth
zurich
macromolecular
crystallographi
softwar
develop
gerard
bricgon
mrc
laboratori
molecular
biolog
investig
tradeoff
protein
stabil
ligand
recognit
theme
lab
cycl
method
develop
experiment
test
led
discoveri
colloid
aggreg
chemoinformat
method
target
identif
structurebas
method
ligand
discoveri
applic
gpcr
work
support
nih
fda
sarscov
proteas
superposit
dockingpredict
subsequ
determin
crystal
structur
nm
invers
agonist
adrenerg
receptor
discov
dock
orang
superpos
crystallograph
result
green
antagon
efficaci
primari
antibiot
ceftazidim
caz
piperacillin
pip
disk
diffus
assay
left
contrast
dockingdiscov
inhibitor
simpli
inhibit
enzym
without
upregul
synerg
primari
antibiot
right
b
lorazepam
left
ogerin
middl
model
bind
site
ogerin
howev
potent
specif
irwin
